This inventor holds 1 USPTO granted patent. Top assignee: Actelion Pharmaceuticals Ltd. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Gary Arnold Palmer: Innovator in Pulmonary Arterial Hypertension Treatment
Introduction
Gary Arnold Palmer is a notable inventor based in Titusville, NJ (US). He has made significant contributions to the field of medicine, particularly in the treatment of pulmonary arterial hypertension. His innovative approach has led to the development of methods that enhance patient care and treatment outcomes.
Latest Patents
Gary Palmer holds a patent for "Transitioning patients treated for pulmonary arterial hypertension to selexipag." This patent outlines methods for transitioning patients who are being treated with a non-selexipag prostacyclin pathway agent (PPA) to selexipag. This advancement is crucial for improving the management of pulmonary arterial hypertension.
Career Highlights
Palmer is associated with Actelion Pharmaceuticals Ltd, a company known for its focus on innovative treatments for pulmonary diseases. His work at Actelion has been instrumental in advancing therapeutic options for patients suffering from pulmonary arterial hypertension.
Collaborations
Throughout his career, Gary has collaborated with esteemed colleagues, including Michael Keating and Johanna Colvin Riesen. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Gary Arnold Palmer's contributions to the field of pulmonary arterial hypertension treatment exemplify the impact of innovation in medicine. His patent and work at Actelion Pharmaceuticals Ltd highlight his commitment to improving patient outcomes.